Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-003733
Filing Date
2025-05-15
Accepted
2025-05-15 17:00:20
Documents
42
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR MAR 2025 cns_i10q-033125.htm   iXBRL 10-Q 378021
2 CERTIFICATION BY CHIEF EXECUTIVE OFFICER cns_ex3101.htm EX-31.1 6847
3 CERTIFICATION BY CHIEF FINANCIAL OFFICER cns_ex3102.htm EX-31.2 6893
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3201.htm EX-32.1 3139
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER cns_ex3202.htm EX-32.2 3200
  Complete submission text file 0001683168-25-003733.txt   2504143

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20250331.xsd EX-101.SCH 19643
7 XBRL CALCULATION FILE cnsp-20250331_cal.xml EX-101.CAL 26063
8 XBRL DEFINITION FILE cnsp-20250331_def.xml EX-101.DEF 101538
9 XBRL LABEL FILE cnsp-20250331_lab.xml EX-101.LAB 203606
10 XBRL PRESENTATION FILE cnsp-20250331_pre.xml EX-101.PRE 168848
44 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-033125_htm.xml XML 230846
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 25955087
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)